

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average burden nours per response 0.5					
nours per response					

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person <sup>*</sup> Dorling Janet	Ct-tt (Mt-				3. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]			
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BOULEVARD, SUITE 110	08/03/2	:019		I:	SSUET (Check Director X Officer (give tit		Filed(Mon	ndment, Date Original th/Day/Year)
(Street) NEWARK, CA 94560			b	below) Chief Commercial Officer			6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned						wned	
1.Title of Security (Instr. 4)		Beneficially Owned (Instr. 4) (D (I)			1	direct (Instr. 5)		
Reminder: Report on a separate line for each class of Persons who respon unless the form disp	d to the c lays a cur	ollection or rently vali	of info	ormation IB contro	contained in to I number.		·	
Table II - Derivative			ľ	· · · ·	• • • • • • • • • • • • • • • • • • • •	T .		ĺ
(Instr. 4)	•		rity	nount of erlying Derivativ	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
_	ate xercisable	Expiration Date	Title	Amount of Shares	or Number of	Security	(D) or Indirect (I) (Instr. 5)	

# **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Dorling Janet C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BOULEVARD, SUITE 110 NEWARK, CA 94560			Chief Commercial Officer		

### **Signatures**

/s/ Janet Dorling	08/05/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

#### No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of SUJAL SHAH, CHARLES MCWHERTER, DANIEL MENOLD, PAUL T. QUINLAN, DIANA KWON, MATTHEW HEMINGTON and BRETT WHI

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of CymaBay Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amen

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exe

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's ho

/s/ Janet Dorling
Janet Dorling